Key result
Novel homozygous MYZAP nonsense variant is linked to atrioventricular septal defects in siblings.
Why the study?
The contributions of structural proteins involved in cardiomyocyte integrity to atrioventricular septal defects remain incompletely understood.
Is a MYZAP mutation associated with atrioventricular septal defects in an Arabian family?
Case Report (n=3)
Is a MYZAP mutation associated with atrioventricular septal defects in an Arabian family?
A novel stop-gain mutation in the MYZAP gene is associated with a spectrum of atrioventricular septal defects in an Arabian family, suggesting a potential role for MYZAP in congenital cardiac septation beyond its known link to cardiomyopathy.
Background Atrioventricular septal defects (AVSDs) represent a diverse group of congenital cardiac malformations arising from abnormal development of the endocardial cushions. Although several transcription factors have been implicated in septation, the contributions of structural proteins involved in cardiomyocyte integrity remain incompletely understood. Methods and Results We investigated an Arabian family presenting with a spectrum of AVSD phenotypes, including complete AVSD, partial AVSD, and an isolated cleft of the anterior mitral leaflet. Whole-exome sequencing identified a novel homozygous stop-gain variant in the MYZAP gene (NM_001018100.5:c.229C > T; p.Arg77Ter) in two affected siblings. Segregation analysis confirmed heterozygous carriage in the father and absence in the unaffected mother. The variant is extremely rare in population databases and meets ACMG criteria for likely pathogenicity. Conclusion This report expands the phenotypic spectrum associated with MYZAP and suggests a potential role in cardiac septation. While MYZAP is primarily linked to cardiomyopathy, our findings raise the possibility that it may contribute to congenital cardiac malformations, potentially through disruption of cardiomyocyte adhesion or developmental signaling pathways controling cardiogenesis. Further functional studies are required to validate this association.
No takes yet. Share an insight, caveat, or question.
Zaher et al. (2026) conducted a case report in Atrioventricular septal defects (AVSD) (n=3). MYZAP stop-gain variant (c.229C > T; p.Arg77Ter) was evaluated on Identification of genetic mutation associated with AVSD. Whole-exome sequencing identified a novel homozygous stop-gain variant in the MYZAP gene (p.Arg77Ter) in two affected siblings with atrioventricular septal defects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: